MedTech Terms
    The authoritative reference
    All terms
    Investment & FinanceStartup Lifecycle

    Post-Money Valuation

    Company valuation immediately after a financing closes.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

    Definition

    Post-money valuation equals pre-money valuation plus the amount of new capital raised. Investor ownership equals investment ÷ post-money.
    What the regulation says
    While 'post-money valuation' is an investment and finance term, its direct impact on regulatory and quality aspects of MedTech is indirect. Regulatory bodies like the FDA or those overseeing EU MDR do not directly regulate company valuations. However, a company's valuation can influence its ability to fund significant regulatory submissions, quality system improvements, or post-market surveillance activities, which are critical under regulations like 21 CFR 820 (Quality System Regulation) and EU MDR Annex III.

    What this means in practice

    Post-money is the headline number in press releases. Founders should focus on the dilution math, not the headline.

    Examples

    • A MedTech startup with a $100 million post-money valuation successfully secures funding to conduct a pivotal clinical trial required for FDA premarket approval (PMA).
    • A company's $20 million post-money valuation, while substantial, is carefully managed to ensure adequate funds are reserved for ongoing post-market surveillance activities mandated by EU MDR Article 83.
    • An investor evaluating a MedTech company with a high post-money valuation examines its cash burn rate to confirm sustained funding for achieving compliance with ISO 13485:2016 quality management system requirements.
    Common pitfalls
    • •A high post-money valuation does not guarantee regulatory approval or product market success.
    • •Confusing a high valuation with adequate funding for long-term regulatory compliance can lead to underestimation of compliance costs.
    • •Failing to allocate sufficient capital from funding rounds, regardless of valuation, for critical quality and regulatory personnel can hinder compliance.
    • •Assuming investors fully understand the financial requirements for MedTech regulatory clearances and post-market obligations.

    Frequently asked questions

    Post-money valuation reflects the company's total estimated value after receiving new investment. While not a regulatory metric itself, a higher valuation can indicate greater financial resources, which are essential for funding the often-expensive regulatory processes, quality system implementation, and post-market activities required by authorities such as the FDA or under the EU MDR.
    Grouped by theme

    Primary references

    3 sources
    Link health: 3 verified· last checked 2026-06-20
    PitchBook·1NVCA·1SVB·1
    1. 1
      PitchBook - MedTech Coverage
      Verified
      PitchBookpitchbook.com
    2. 2
      NVCA Model Documents
      Verified
      NVCAnvca.org
    3. 3
      Silicon Valley Bank - Healthcare Reports
      Verified
      SVBsvb.com

    Inline markers like [1] jump to the matching reference above.